CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
Combination Therapy of Pegylated Interferon alpha 2b (PegIFN) and Adefovir Dipivoxil (ADV) in Chronic Hepatitis B (CH-B) Patients Reduces the Reservoir of Transcriptionally Active cccDNA and Hepatitis B Surface Antigen (HBsAg)
DOI 10.1055/s-2005-862299
Bibliografische Angaben
Nachweis in CareLit
Autor:innenF Metzler, K Wursthorn, B Zoellner, P Buggisch, M Zankel, C Fischer, J Petersen
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe01/2005
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: We previously demonstrated that 48 weeks of ADV therapy resulted in a significant median 73% reduction of serum HBsAg (Werle, Gastroenterology 2004). Changes in HBsAg were significantly and positively correlated with changes in intrahepatic cccDNA, total intrahepatocellular HBV DNA and serum HBV DNA. The number of HBcAg positive hepatocytes remained stable. Aim: To determine the reduction of serum HBsA…
Zitieren
Zitierempfehlung
F Metzler, K Wursthorn, B Zoellner, P Buggisch, M Zankel, C Fischer, J Petersen (2005) Combination Therapy of Pegylated Interferon alpha 2b (PegIFN) and Adefovir Dipivoxil (ADV) in Chronic Hepatitis B (CH-B) Patients Reduces the Reservoir of Transcriptionally Active cccDNA and Hepatitis B Surface Antigen (HBsAg). Zeitschrift für Gastroenterologie (01). https://doi.org/10.1055/s-2005-862299
Mit CareLit weiterarbeiten